Off-Label Use of GLP-1 Agonists and SGLT-2 Inhibitors in Type 1 Diabetes

In a real-world study, metabolic outcomes were more favorable with GLP-1 agonists than with SGLT-2 inhibitors.

Glucagon-like peptide-1 (GLP-1) agonists and sodium–glucose transport protein-2 (SGLT-2) inhibitors are not U.S. FDA-approved for patients with type 1 diabetes, but some clinicians prescribe these drugs off-label for such patients. In this retrospective, single-center study, researchers examined outcomes for 104 adults with type 1 diabetes who received either of these agents for an average of 2 years; 65 patients received only GLP-1 agonists, 28 received only SGLT-2 inhibitors, and 11 received both.

Mean age was ≈44, mean weight was ≈90 kg, mean glycosylated hemoglobin (HbA_1c) was ≈7.8%, and mean total daily insulin dose was ≈60 units. Key outcomes were as follows:

At 12 months, GLP-1 agonists were associated with statistically significant re…

Reviewing Author

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Off-Label Use of GLP-1 Agonists and SGLT-2 Inhibitors in Type 1 Diabetes

Topics

Reviewing Author